StockTipsArenaBeta

BUY Cohance Lifesciences Limited — BOB Capital Markets

BUYCohance Lifesciences Limited
Cohance Lifesciences share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)14 Aug 2025via Institutional / Brokerage Research

Entry₹913.85Inferred
Target₹1,240
Total upside +35.69% (call closed)
Stop lossNot given
At expiry₹444.214 Aug 2026, 3:30 pm
Expired-51.39%
Follow BOB Capital Markets for new calls(63% target hit, 358 closed calls)Get alertsWatch COHANCE for new buy/sell callsGet alertsSee 4 active Long-term calls on COHANCESee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Aug 2026
3 supporting3 neutral4 opposing
Supports the BUY call (3)

Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why

NewsNdtv-Profit·6 Aug · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·6 Aug · 1w ago

Neutral / worth noting (3)

Cohance Lifesciences’ Hyderabad plant gets USFDA observations: What it means for the pharma maker

NewsCnbc-Tv18·5 Aug · 1w ago

(opens in new tab)

Cohance Lifesciences Limited announced its unaudited financial results for Q1FY27, reporting revenue of ₹4,223 million (down 23.1% YoY) and adjusted EBITDA of ₹92 million. The company expects a reboun

NSE · Press Release·5 Aug · 1w ago

(opens in new tab)

Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (4)

Cohance Lifesciences Q1 Review: Brokerages Split After Earnings Slump — Check Potential Upside, Target Price

NewsNdtv-Profit·6 Aug · 1w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·6 Aug · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cohance Lifesciences

All analyst calls on Cohance Lifesciences

More from BOB Capital Markets

Every call and its outcome